J. Mehilli, MD, G. Richard, F-J. Neumann, S. Massberg, K-L. Laugwitz, J. Pache, J. Hausleiter, I. Ott, M. Fusaro, T. Ibrahim, A. Schömig, A. Kastrati Deutsches.

Slides:



Advertisements
Similar presentations
Prospective, Randomized Trial of Paclitaxel- versus Sirolimus- Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents Robert A.
Advertisements

The value of DES in unprotected left main lesions has not been evaluated by dedicated randomized clinical trials. Especially, it is not known whether currently.
J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig Abciximab in Patients.
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
ISAR-REACT 2 ESC 2007 M. Seyfarth, A. Kastrati, J. Mehilli, F.-J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, J. Pache, J. Dirschinger, P. B. Berger,
ISAR-TEST-2 Trial Two-year Clinical and Angiographic Outcomes from a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents versus Polymer-Based Cypher.
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
ISAR-TEST 5: Randomized, Non-inferiority Trial of Rapamycin/Probucol- and Zotarolimus-Eluting Stents J. Mehilli, MD A. Kastrati, R.A. Byrne, S. Massberg,
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Clinical Result Overview
Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Tarunjit Singh Department of Internal Medicine Westchester Medical Center New York Medical College Valhalla NY.
Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
ISAR REACT 3 A. Kastrati, F.-J. Neumann, J. Mehilli, S. Schulz, G. Richardt, R. Iijima, R.A. Byrne, P.B. Berger, A. Schömig Bivalirudin Versus Unfractionated.
Maurizio Menichelli MD San Camillo Hospital, Rome ( SESAMI Trial) Maurizio Menichelli Presenter Disclosure Information Nothing to Disclose Randomized trial.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
LBCT March 29, 08 ISAR REACT 3 A. Kastrati, F.-J. Neumann, J. Mehilli, S. Schulz, G. Richardt, R. Iijima, R.A. Byrne, P.B. Berger, A. Schömig Bivalirudin.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
Neointimal Modification with Scoring-Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients with Restenosis in Drug- Eluting Coronary Stents Deutsches.
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
LONG-TERM EVENTS IN SIROLIMUS-ELUTING STENTS: a specific focus on diseased saphenous vein grafts from the randomized DELAYED-RRISC trial Pierfrancesco.
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
ROTAXUS A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische Universität Munich, Germany A Polymer-Free Dual Drug-Eluting.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
LBCT March 29, 08 ISAR REACT 3 A. Kastrati, F.-J. Neumann, J. Mehilli, S. Schulz, G. Richardt, R. Iijima, R.A. Byrne, P.B. Berger, A. Schömig Bivalirudin.
Northeast Georgia Heart Center State of the Art Review: Bypass graft Interventions J. Jeffrey Marshall, MD, FSCAI Past President SCAI, Director.
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
ISAR-TEST-2 Trial Two-year Clinical and Angiographic Outcomes from a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents versus Polymer-Based Cypher.
Deutsches Herzzentrum, Technische Universität, Munich, Germany
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
DES Should be Used as the Default Stent in ACS!
Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) - press conference - Katrin.
The RESOLUTE Program: today and tomorrow
On behalf of J. Belardi, M. Leon, L. Mauri,
Long-term follow-up of the DIABETES I (DIABETes and sirolimus Eluting Stent) trial: P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín,
American College of Cardiology Presented by Dr. Stephan Windecker
3-Year Clinical Outcomes From the RESOLUTE US Study
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
Five-Year Cumulative Rates of Clinical Events after Cypher™ Stent Implantation: Insights from a Patient-Level Pooled Analysis of Four Randomized Trials.
The American College of Cardiology Presented by Dr. Raimund Erbel
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Impact of Diabetes Mellitus on Long-term Outcomes in the
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Deutsches Herzzentrum, Technische Universität, Munich, Germany
Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
The American College of Cardiology Presented by Dr. A. Abazid
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presentation transcript:

J. Mehilli, MD, G. Richard, F-J. Neumann, S. Massberg, K-L. Laugwitz, J. Pache, J. Hausleiter, I. Ott, M. Fusaro, T. Ibrahim, A. Schömig, A. Kastrati Deutsches Herzzentrum & 1st Med. Klinik rechts der Isar, Technische Universität Munich, Germany ISAR-CABG: Randomized, Superiority Trial of Drug-Eluting-Stent and Bare Metal Stent in Safenous Vein Graft Lesions

Disclosure Statement of Financial Interest Lecture fees from Abbott Vascular

Background Years After Randomization Patients at Risk SES BMS Sirolimus-eluting stent Bare metal stent Probability of Death, MI and Reintervention, % HR 0.43 (0.34, 0.54) 14 Trials, 4958 pts DES are more effective and as safe as their BMS predecessors in native coronary artery lesions Kastrati …Schömig, NEJM 2007 HR 0.46 (0.38, 0.55) 5 Trials, 3513 pts Stone …Leon, NEJM 2007

DES vs. BMS in Saphenous Vein Graft Lesions Vermeersch et al., JACC 2007 DELAYED RRISC Trial N=75 months % TLR P=.55 Survival SES BMS

All-cause DeathTarget Lesion Revascularization Cardiac death 7% (PES) vs. 13% (BMS) HR 0.62 [ ]; P=0.51 DES vs. BMS in Saphenous Vein Graft Lesions Brilakis et al., JACC Intv 2011 SOS Trial N=80

Objective of the of ISAR-CABG Trial: …to compare the efficacy of drug-eluting stents against bare metal stents – in a trial powered for clinical events Participating Centers Deutsches Herzzentrum Munich 1.Med. Klinik, Klinikum rechts der Isar, Munich Herzzentrum Bad Krozingen, Bad Krozingen Bad Segeberger Kliniken, Bad Segeberg Germany

Inclusion criteria Patients with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥50 % de novo stenosis located in saphenous vein grafts Informed, written consent Exclusion criteria Cardiogenic shock Target lesion located in arterial grafts Malignancies with life expectancy <1 year Allergies to study medication Patient Selection

Composite of death, myocardial infarction ischemia-related target lesion revascularization at 1-year post index PCI Primary Endpoint

Secondary Endpoints All cause mortality Myocardial infarction Ischemia-related target lesion revascularization Incidence of definite/probable stent thrombosis at 1-year post index PCI

Sample Size Calculation Hypothesis: Drug-eluting stent (DES) is superior to bare metal stent (BMS) in terms of major adverse cardiac events Assumptions: Incidence of primary endpoint in BMS group of 30% Reduction of MACE with DES of 33% Power of 80%  -level of 0.05 Total number of patients needed: 600 (accounting for possible losses at follow-up)

DES (Cypher/Taxus/BP Sirolimus) n=303 BMS n= patients with de novo SVG lesions Is Drug-Eluting Stenting Associated With Improved Results in Coronary Artery Bypass Grafts? ISAR-CABG 6 to 8-month repeat angiogram (encouraged) 12-month clinical follow-up

serial CK + CKMB measurements 600 mg Clopidogrel PCI ASS 500 mg 0 repeat angiography clinical follow-up 6-8 mo. 12 mo. Follow-Up Protocol 30 d clinical follow-up Clopidogrel2x75 mg/day until discharge 75 mg at least 6 months after index PCI Aspirin200 mg/d indefinitely

DES n=303 BMS n=307 Age, years71.4± ± 9.3 Female, %1316 Art. hypertension, %7173 Diabetes, %3735 Current smoker, %86 Hyperlipidemia, %8886 SVG age, years13.8± ± 5.1 History of MI, %5655 Baseline clinical characteristics

DES n=303 BMS n=307 Clinical presentation, % acute MI1713 unstable angina2127 stable angina6260 Multivessel disease, %9899 Multilesion PCI, %2422 >1 SVGs treated/patient, % LV ejection fraction, %49.2± ± 13.8 Baseline clinical characteristics, II

Angiographic characteristics DES n=386 BMS n=385 Recipient vessel, % LAD/diagonal LCx/marginal RCA/PDA33.0 Vessel size, mm3.36± ± 0.73 Total stented length, mm26.8± ± 17.7

DES % >75%50%-75%25%-50% Distribution of SVG Degeneration Score < 25% BMS %

DES % medialproximalcoronary Distribution of Lesion Location within the SVGs aortal BMS % distaldiffuse

% % Distribution of TIMI Flow Rates DESBMSDESBMS Prior to PCI After PCI TIMI 3TIMI 2TIMI 1TIMI 0

30-Day Clinical Outcomes % BMS DES P=.57P=.66P=.07P=.05 Cardiac deathMyocardial infarction * No TLR occurred and only 1 pt (DES) died suddenly (probable stent thrombosis) during 30-day follow-up MACE*All-cause death

Months After Randomization Cumulative Incidence (%) Primary Endpoint: Death/MI/TLR 22.1% 15.4% P=.03 RR 0.65 [ ] BMS DES

All-cause Death Months After Randomization Cumulative Incidence (%) 4.7% 5.2% P=.82 RR 1.09 [ ] BMS DES

Months After Randomization Cumulative Incidence (%) Myocardial Infarction 6.0% 4.2% P=.27 RR 0.66 [ ] BMS DES

Death or Myocardial Infarction Cumulative Incidence (%) P=.27 RR 0.75 [ ] BMS DES Months After Randomization % 8.5%

Definite/Probable Stent Thrombosis Months After Randomization Cumulative Incidence (%) P=.99 RR 1.01 [ ] BMS DES 0.7%

Target Lesion Revascularization Cumulative Incidence (%) P=.02 RR 0.52 [ ] BMS DES 13.1% 7.2% Months After Randomization

Target Vessel Revascularization % BMSDES TLR % TVR P=.02 RR 0.52 [ ] P=.03 RR 0.61 [ ]

Summary Out to 12 months drug-eluting stents are superior to bare metal stents in a large-scale study powered for clinical endpoints. The need for repeat revascularizations was reduced by ~50% with DES as compared to BMS. DES were comparable to BMS regarding safety parameters – stent thrombosis, death or MI.